Publication Date
In 2024 | 0 |
Since 2023 | 0 |
Since 2020 (last 5 years) | 1 |
Since 2015 (last 10 years) | 2 |
Since 2005 (last 20 years) | 2 |
Descriptor
Autism | 2 |
Drug Therapy | 2 |
Pervasive Developmental… | 2 |
Adolescents | 1 |
Check Lists | 1 |
Interpersonal Competence | 1 |
Intervention | 1 |
Neurological Organization | 1 |
Neurology | 1 |
Outcomes of Treatment | 1 |
Program Effectiveness | 1 |
More ▼ |
Source
Journal of Autism and… | 2 |
Author
Erickson, Craig A. | 2 |
Pedapati, Ernest V. | 2 |
Shaffer, Rebecca C. | 2 |
Wink, Logan K. | 2 |
Adams, Ryan | 1 |
Bantel, Andrew P. | 1 |
Dominick, Kelli R. | 1 |
Hong, Michael | 1 |
Horn, Paul | 1 |
Horn, Paul S. | 1 |
O'Brien, Kaela | 1 |
More ▼ |
Publication Type
Journal Articles | 2 |
Reports - Research | 2 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Wink, Logan K.; Reisinger, Debra L.; Horn, Paul; Shaffer, Rebecca C.; O'Brien, Kaela; Schmitt, Lauren; Dominick, Kelli R.; Pedapati, Ernest V.; Erickson, Craig A. – Journal of Autism and Developmental Disorders, 2021
Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose,…
Descriptors: Autism, Pervasive Developmental Disorders, Neurology, Adolescents
Wink, Logan K.; Adams, Ryan; Horn, Paul S.; Tessier, Charles R.; Bantel, Andrew P.; Hong, Michael; Shaffer, Rebecca C.; Pedapati, Ernest V.; Erickson, Craig A. – Journal of Autism and Developmental Disorders, 2018
Riluzole is a glutamatergic modulator of particular interest in autism spectrum disorder (ASD). In this 12-week randomized, double-blind, placebo-controlled, crossover pilot study we evaluated the safety and tolerability of 5-week of adjunctive riluzole treatment (vs. 5-week of placebo, with 2-week washout period) targeting ASD-associated…
Descriptors: Drug Therapy, Autism, Pervasive Developmental Disorders, Safety